Johnson & Johnson (NYSE:JNJ) Shares Bought by Trust Co. of Vermont

Posted by Defense World Staff on Jun 21st, 2023

Trust Co. of Vermont lifted its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 156,585 shares of the company’s stock after acquiring an additional 2,449 shares during the quarter. Johnson & Johnson comprises about 1.7% of Trust Co. of Vermont’s investment portfolio, making the stock its 8th biggest holding. Trust Co. of Vermont’s holdings in Johnson & Johnson were worth $24,271,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in JNJ. DORCHESTER WEALTH MANAGEMENT Co lifted its holdings in Johnson & Johnson by 8.6% in the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after acquiring an additional 5,327 shares during the last quarter. Cantor Fitzgerald Investment Advisor L.P boosted its holdings in Johnson & Johnson by 88.9% during the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock worth $31,049,000 after buying an additional 82,429 shares in the last quarter. AMI Investment Management Inc. grew its position in Johnson & Johnson by 8.8% in the first quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock worth $3,244,000 after buying an additional 1,475 shares during the last quarter. Equitable Holdings Inc. increased its holdings in shares of Johnson & Johnson by 4.9% in the first quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock valued at $8,095,000 after buying an additional 2,119 shares in the last quarter. Finally, USS Investment Management Ltd lifted its position in shares of Johnson & Johnson by 2.4% during the 1st quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock valued at $152,488,000 after acquiring an additional 20,528 shares during the last quarter. Institutional investors own 67.57% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $164.13 on Wednesday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07. The firm has a market cap of $426.53 billion, a PE ratio of 34.34, a PEG ratio of 2.80 and a beta of 0.54. The firm’s 50 day moving average price is $160.72 and its 200 day moving average price is $163.68. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $183.35.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. The business had revenue of $24.75 billion for the quarter, compared to the consensus estimate of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. Johnson & Johnson’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.67 EPS. As a group, research analysts expect that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd were issued a dividend of $1.19 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date of this dividend was Monday, May 22nd. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.90%. Johnson & Johnson’s dividend payout ratio is currently 99.58%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on JNJ shares. Citigroup started coverage on Johnson & Johnson in a research report on Tuesday, May 30th. They set a “buy” rating and a $185.00 target price on the stock. Morgan Stanley raised their target price on shares of Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 19th. StockNews.com initiated coverage on shares of Johnson & Johnson in a research report on Thursday, May 18th. They issued a “strong-buy” rating for the company. Credit Suisse Group lifted their price objective on shares of Johnson & Johnson from $168.00 to $170.00 in a research report on Friday, May 5th. Finally, Guggenheim began coverage on Johnson & Johnson in a research report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 target price for the company. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $171.57.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the sale, the executive vice president now owns 65,934 shares of the company’s stock, valued at $10,549,440. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.20% of the stock is owned by company insiders.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.